FindTrial
Sign In

Expressiom of Programmed death ligand-1(PD-L1)and Forkhead Box P3 (FOXP3) in HER 2 NEU positive breast carcinoma and its association with clinico pathological parameters

Expression of Programmed death ligand-1(PD-L1)and Forkhead Bos P3 (FOXP3) in HER 2 NEU positive breast carcinoma and its association with clinico pathological parameters - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/105549
Enrollment
30
Registered
2026-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Planning branch
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients with a diagnosis of breast carcinoma showing Her 2 neu positivity 2. Patients aged 18 years and above.

Exclusion criteria

Exclusion criteria: 1. Patients who have received radiotherapy 2. Patients showing complete response to chemotherapy.

Design outcomes

Primary

MeasureTime frame
1. To determine the proportion of cases showing PD-L1 positivity in Her 2 Neu positive cases of breast carcinoma. 2. To determine the proportion of cases showing FOXP3 positivity in Her 2 Neu positive cases of breast carcinoma.Timepoint: 1. To determine the proportion of cases showing PD-L1 positivity in Her 2 Neu positive cases of breast carcinoma(baseline). 2. To determine the proportion of cases showing FOXP3 positivity in Her 2 Neu positive cases of breast carcinoma(baseline).—

Secondary

MeasureTime frame
To determine the proportion of cases showing FOXP3 & PD-L1 expression across various clinicopathological parameters such as tumour grade size & lymph node status in Her 2 neu positive cases of breast carcinomaTimepoint: Before & after chemotherapy Time between chemotherapy & modified radical mastectomy—

Countries

India

Contacts

Public ContactKeerthi V

Maulana Azad Medical College

shra_mana@hotmail.com9811686401

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026